Cargando…

Advances in the diagnosis and early management of gestational trophoblastic disease

Gestational trophoblastic disease describes a group of rare pregnancy related disorders that span a spectrum of premalignant and malignant conditions. Hydatidiform mole (also termed molar pregnancy) is the most common form of this disease. Hydatidiform mole describes an abnormal conceptus containing...

Descripción completa

Detalles Bibliográficos
Autores principales: Joyce, Caroline M, Fitzgerald, Brendan, McCarthy, Tommie V, Coulter, John, O'Donoghue, Keelin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9978730/
https://www.ncbi.nlm.nih.gov/pubmed/36936581
http://dx.doi.org/10.1136/bmjmed-2022-000321
_version_ 1784899581578838016
author Joyce, Caroline M
Fitzgerald, Brendan
McCarthy, Tommie V
Coulter, John
O'Donoghue, Keelin
author_facet Joyce, Caroline M
Fitzgerald, Brendan
McCarthy, Tommie V
Coulter, John
O'Donoghue, Keelin
author_sort Joyce, Caroline M
collection PubMed
description Gestational trophoblastic disease describes a group of rare pregnancy related disorders that span a spectrum of premalignant and malignant conditions. Hydatidiform mole (also termed molar pregnancy) is the most common form of this disease. Hydatidiform mole describes an abnormal conceptus containing two copies of the paternal genome, which is classified as partial when the maternal genome is present or complete when the maternal genome is absent. Hydatidiform mole typically presents in the first trimester with irregular vaginal bleeding and can be suspected on ultrasound but confirmation requires histopathological evaluation of the products of conception. Most molar pregnancies resolve without treatment after uterine evacuation, but occasionally the disease persists and develops into gestational trophoblastic neoplasia. Close monitoring of women after molar pregnancy, with regular measurement of human chorionic gonadotrophin concentrations, allows for early detection of malignancy. Given the rarity of the disease, clinical management and treatment is best provided in specialist centres where very high cure rates are achievable. This review looks at advances in the diagnosis and early management of gestational trophoblastic disease and highlights updates to disease classification and clinical guidelines. Use of molecular genotyping for improved diagnostic accuracy and risk stratification is reviewed and future biomarkers for the earlier detection of malignancy are considered.
format Online
Article
Text
id pubmed-9978730
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher BMJ Publishing Group
record_format MEDLINE/PubMed
spelling pubmed-99787302023-03-16 Advances in the diagnosis and early management of gestational trophoblastic disease Joyce, Caroline M Fitzgerald, Brendan McCarthy, Tommie V Coulter, John O'Donoghue, Keelin BMJ Med Review Gestational trophoblastic disease describes a group of rare pregnancy related disorders that span a spectrum of premalignant and malignant conditions. Hydatidiform mole (also termed molar pregnancy) is the most common form of this disease. Hydatidiform mole describes an abnormal conceptus containing two copies of the paternal genome, which is classified as partial when the maternal genome is present or complete when the maternal genome is absent. Hydatidiform mole typically presents in the first trimester with irregular vaginal bleeding and can be suspected on ultrasound but confirmation requires histopathological evaluation of the products of conception. Most molar pregnancies resolve without treatment after uterine evacuation, but occasionally the disease persists and develops into gestational trophoblastic neoplasia. Close monitoring of women after molar pregnancy, with regular measurement of human chorionic gonadotrophin concentrations, allows for early detection of malignancy. Given the rarity of the disease, clinical management and treatment is best provided in specialist centres where very high cure rates are achievable. This review looks at advances in the diagnosis and early management of gestational trophoblastic disease and highlights updates to disease classification and clinical guidelines. Use of molecular genotyping for improved diagnostic accuracy and risk stratification is reviewed and future biomarkers for the earlier detection of malignancy are considered. BMJ Publishing Group 2022-12-16 /pmc/articles/PMC9978730/ /pubmed/36936581 http://dx.doi.org/10.1136/bmjmed-2022-000321 Text en © Author(s) (or their employer(s)) 2022. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ. https://creativecommons.org/licenses/by-nc/4.0/This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/ (https://creativecommons.org/licenses/by-nc/4.0/) .
spellingShingle Review
Joyce, Caroline M
Fitzgerald, Brendan
McCarthy, Tommie V
Coulter, John
O'Donoghue, Keelin
Advances in the diagnosis and early management of gestational trophoblastic disease
title Advances in the diagnosis and early management of gestational trophoblastic disease
title_full Advances in the diagnosis and early management of gestational trophoblastic disease
title_fullStr Advances in the diagnosis and early management of gestational trophoblastic disease
title_full_unstemmed Advances in the diagnosis and early management of gestational trophoblastic disease
title_short Advances in the diagnosis and early management of gestational trophoblastic disease
title_sort advances in the diagnosis and early management of gestational trophoblastic disease
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9978730/
https://www.ncbi.nlm.nih.gov/pubmed/36936581
http://dx.doi.org/10.1136/bmjmed-2022-000321
work_keys_str_mv AT joycecarolinem advancesinthediagnosisandearlymanagementofgestationaltrophoblasticdisease
AT fitzgeraldbrendan advancesinthediagnosisandearlymanagementofgestationaltrophoblasticdisease
AT mccarthytommiev advancesinthediagnosisandearlymanagementofgestationaltrophoblasticdisease
AT coulterjohn advancesinthediagnosisandearlymanagementofgestationaltrophoblasticdisease
AT odonoghuekeelin advancesinthediagnosisandearlymanagementofgestationaltrophoblasticdisease